In the same report, a repeat dose of ARO‐ANG3 (Day 1 and Day 29) also achieved a substantial and sustained decrease in serum ANGPTL3 (−85%), triglyceride (−47%), non‐HDL‐cholesterol (−37%), VLDL‐C (−43.5%) and LDL‐C (−35%) concentrations, with the 200 mg dose in participants with baseline hepatic steatosis (Cohort 5), with no meaningful adverse changes in liver fat observed with ARO‐ANG3 treatment. The gene discussed is ANGPTL3; the disease is fatty liver disease.